Semin Radiat Oncol 1992, 2:31–33 CrossRef 2 Ang KK, Peters LJ, W

Semin Radiat Oncol 1992, 2:31–33.CrossRef 2. Ang KK, Peters LJ, Weber RS: Concomitant boost radiotherapy schedules

in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990, 19:1339–1345.PubMedCrossRef 3. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R: Radiobiological considerations in the design of fractionation https://www.selleckchem.com/products/a-769662.html strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000,46(3):619–630.PubMedCrossRef 4. Dogan N, King S, Emami B, Mohideen N, Mirkovic N, Leybovich LB, Sethi A: Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003, 57:1480–1491.PubMedCrossRef TGF-beta/Smad inhibitor 5. Fogliata A, Bolsi A, Cozzi L, Bernier J: Comparative dosimetric evaluation of the simultaneous integrated boost with photon intensity modulation in head and neck cancer patients. Radiother Oncol 2003,

69:267–275.PubMedCrossRef 6. Strigari L, D’Andrea M, Abate A, Benassi M: A heterogeneous dose distribution in simultaneous integrated boost: the role of the clonogenic cell density on the tumor control probability. Phys Med Biol 2008, 53:5257–5273.PubMedCrossRef 7. Stavrev P, Hristov D: Prostate IMRT fractionation strategies: two-phase treatment versus simultaneous integrated boost. Radiol Oncol 2003, 37:115–126. 8. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R: Radiobiological considerations in the design of fractionation strategies

for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000, 46:619–630.PubMedCrossRef 9. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109–122.PubMed 10. Strigari L, Arcangeli G, Arcangeli S, Benassi M: Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:1454–1460.PubMedCrossRef PARP inhibitor 11. Marzi S, Arcangeli G, Saracino B, Petrongari MG, Bruzzaniti V, Iaccarino G, Landoni V, Soriani A, Benassi M: Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:41–49.PubMedCrossRef 12. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, Cozzarini C, Fellin G, Foppiano F, Girelli G, Menegotti L, Piazzolla A, Vavassori V, Valdagni R: Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004, 73:21–32.PubMedCrossRef 13. Abate A, Pressello MC, Benassi M, Strigari L: Comparison of IMRT planning with two-step and one-step https://www.selleckchem.com/products/4egi-1.html optimization: a strategy for improving therapeutic gain and reducing the integral dose. Phys Med Biol 2009,54(23):7183–98.

Comments are closed.